0.6 C
New York
Wednesday, February 1, 2023

It’s Not Over Yet For Novavax Inc. (NASDAQ: NVAX)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Novavax Inc. (NVAX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.08, or -0.68%, to $11.63. The Novavax Inc. has recorded 491,564 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Stocks Info

Novavax Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $11.71 and fluctuated between $12.02 as its day high and $10.57 as its day low. The current market capitalization of Novavax Inc. is $940.90M. A total of 9.15 million shares were traded on the day, compared to an average of 6.46M shares.

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, NVAX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 16 BUYs and 12 SELLs from insiders. Insiders purchased 27,012 shares during that period but sold 20,760.

In the most recent transaction, YOUNG JAMES F sold 12,500 shares of NVAX for 73.58 per share on Mar 31. After the transaction, the Director now owns 62,590 company shares.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for NVAX in the last 3 months, the mean price target is $68.40 with high estimates of $110.00 and low estimates of $13.00. In terms of 52-week highs and lows, NVAX has a high of $139.60 and a low of $8.75.

As of this writing, NVAX has an earnings estimate of $1.58 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of $3.76 per share and a lower estimate of -$0.81. The company reported an EPS of $2.56 in the last quarter, which was -4.80% lower than expectations of $2.69.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 6 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NVAX is Overweight with a score of 3.43. A total of 4 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles